Equities Analysts Issue Forecasts for ABVX FY2025 Earnings

ABIVAX Société Anonyme (NASDAQ:ABVX) – Leerink Partnrs dropped their FY2025 EPS estimates for ABIVAX Société Anonyme in a report released on Monday, March 24th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($3.36) per share for the year, down from their previous forecast of ($3.00). The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme’s FY2026 earnings at ($3.25) EPS, FY2027 earnings at ($2.91) EPS, FY2028 earnings at ($2.31) EPS and FY2029 earnings at ($0.26) EPS.

A number of other research analysts have also weighed in on ABVX. Morgan Stanley restated an “equal weight” rating and issued a $12.00 target price on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th. JMP Securities reissued a “market outperform” rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. Finally, Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $38.00.

ABIVAX Société Anonyme Trading Down 3.8 %

ABVX stock opened at $6.82 on Thursday. The business has a 50-day simple moving average of $6.79 and a two-hundred day simple moving average of $8.41. ABIVAX Société Anonyme has a 52-week low of $5.50 and a 52-week high of $16.63.

Institutional Trading of ABIVAX Société Anonyme

A number of institutional investors and hedge funds have recently modified their holdings of ABVX. Kennedy Capital Management LLC boosted its position in ABIVAX Société Anonyme by 0.7% in the fourth quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company’s stock worth $1,650,000 after purchasing an additional 1,656 shares during the last quarter. Bank of America Corp DE raised its stake in shares of ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the period. GAMMA Investing LLC purchased a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth about $29,000. R Squared Ltd bought a new position in ABIVAX Société Anonyme during the fourth quarter valued at about $36,000. Finally, BNP Paribas Financial Markets raised its position in ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the period. 47.91% of the stock is owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.